Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + trametinib ± ipilimumab in metastatic colorectal cancer
NCT03377361Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2018
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label trial of nivolumab in colorectal cancer (CRC) (6 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Dose Limiting Toxicities at 8 weeks, Safety Related Events at 5.5 months and 3 more. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03377361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377361.